319,663 Shares of Sensei Biotherapeutics, Inc. $FTH Acquired by Candriam S.C.A.

Candriam S.C.A. bought a new position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) in the 3rd quarter, HoldingsChannel.com reports. The fund bought 319,663 shares of the company’s stock, valued at approximately $9,542,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Vivo Capital LLC acquired a new stake in shares of Sensei Biotherapeutics in the 1st quarter valued at approximately $22,758,000. Stempoint Capital LP bought a new stake in shares of Sensei Biotherapeutics during the 1st quarter valued at approximately $4,188,000. Alyeska Investment Group L.P. bought a new stake in shares of Sensei Biotherapeutics during the 2nd quarter valued at approximately $3,610,000. Bank of America Corp DE grew its holdings in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after purchasing an additional 20,525 shares in the last quarter. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Stock Performance

FTH opened at $12.68 on Tuesday. Sensei Biotherapeutics, Inc. has a twelve month low of $7.45 and a twelve month high of $42.14. The business’s fifty day moving average price is $27.04. The firm has a market capitalization of $327.65 million, a PE ratio of -0.09 and a beta of -0.15.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13). On average, equities research analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

FTH has been the subject of several research reports. Lifesci Capital raised shares of Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, October 15th. Raymond James Financial assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, July 31st. They set an “outperform” rating and a $56.00 target price on the stock. William Blair initiated coverage on shares of Sensei Biotherapeutics in a research note on Friday, October 16th. They set an “outperform” rating on the stock. Needham & Company LLC assumed coverage on shares of Sensei Biotherapeutics in a report on Friday, August 21st. They set a “buy” rating and a $56.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sensei Biotherapeutics has a consensus rating of “Moderate Buy” and an average target price of $56.17.

Sensei Biotherapeutics Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.